abstract |
The present invention relates to a method of treating tumors with KRAS mutations comprising the compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H) -isoindole-4-oxy)-5-trifluoromethyl-pyrimidin-2-yl)amino]-N-(1-methyl-piperidin-4-yl)benzamide or a pharmaceutically acceptable salt thereof alone or in combination with a KRAS inhibitor and/or a MEK inhibitor. |